Lauri Chiara, Campagna Giuseppe, Glaudemans Andor W J M, Slart Riemer H J A, van Leer Bram, Pillay Janesh, Colandrea Marzia, Grana Chiara Maria, Stigliano Antonio, Signore Alberto
Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Sant'Andrea University Hospital, "Sapienza" University of Rome, 00161 Rome, Italy.
Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Biomedicines. 2023 Oct 26;11(11):2899. doi: 10.3390/biomedicines11112899.
Since most endocrine glands express ACE-2 receptors and can be infected by SARS-CoV-2 virus, this retrospective multicentre observational study aims to assess the metabolic activity of thyroid and adrenal glands of COVID-19 patients by F-FDG PET/CT.
We retrospectively evaluated the F-FDG PET/CT scans of COVID-19 patients admitted by three different centres, either in a low-intensity department or in the intensive care unit (ICU). A visual assessment and a semi-quantitative evaluation of areas of interest in thyroid and adrenal glands were performed by recording SUVmax and SUVmean. The F-FDG PET/CT uptake in COVID-19 patients was compared with those observed in normal age-matched controls.
Between March 2020 and March 2022, 33 patients from three different centres (twenty-eight patients in a low-intensity department and five patients in ICU), were studied by F-FDG PET/CT during active illness. Seven of them were also studied after clinical remission (3-6 months after disease onset). Thirty-six normal subjects were used as age-matched controls. In the thyroid gland, no statistically significant differences were observed between control subjects and COVID-19 patients at diagnosis. However, at the follow-up PET/CT study, we found a statistically higher SUVmax and SUVmean ( = 0.009 and = 0.004, respectively) in the thyroid of COVID-19 patients. In adrenal glands, we observed lower SUVmax and SUVmean in COVID-19 patients at baseline compared to control subjects ( < 0.0001) and this finding did not normalize after clinical recovery ( = 0.0018 for SUVmax and = 0.002 for SUV mean).
In our series, we observed persistent low F-FDG uptake in adrenal glands of patients at diagnosis of COVID-19 and after recovery, suggesting a chronic hypofunction. By contrast, thyroid uptake was comparable to normal subjects at disease onset, but after recovery, a subgroup of patients showed an increased metabolism, thus possibly suggesting the onset of an inflammatory thyroiditis. Our results should alert clinicians to investigate the pituitary-adrenal axis and thyroid functionality at the time of infection and to monitor them after recovery.
由于大多数内分泌腺表达血管紧张素转换酶2(ACE-2)受体且可被严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒感染,这项回顾性多中心观察性研究旨在通过F-FDG PET/CT评估新型冠状病毒肺炎(COVID-19)患者甲状腺和肾上腺的代谢活性。
我们回顾性评估了由三个不同中心收治的COVID-19患者的F-FDG PET/CT扫描结果,这些患者分别入住低强度科室或重症监护病房(ICU)。通过记录最大标准化摄取值(SUVmax)和平均标准化摄取值(SUVmean),对甲状腺和肾上腺感兴趣区域进行了视觉评估和半定量评估。将COVID-19患者的F-FDG PET/CT摄取情况与年龄匹配的正常对照者的观察结果进行比较。
在2020年3月至2022年3月期间,对来自三个不同中心的33例患者(28例在低强度科室,5例在ICU)在疾病活动期进行了F-FDG PET/CT研究。其中7例患者在临床缓解后(发病后3 - 6个月)也接受了研究。36名正常受试者作为年龄匹配的对照。在甲状腺方面,诊断时对照者与COVID-19患者之间未观察到统计学上的显著差异。然而,在随访的PET/CT研究中,我们发现COVID-19患者甲状腺的SUVmax和SUVmean在统计学上更高(分别为P = 0.009和P = 0.004)。在肾上腺方面,与对照者相比,COVID-19患者基线时的SUVmax和SUVmean较低(P < 0.0001),且临床恢复后这一发现并未恢复正常(SUVmax为P = 0.0018,SUVmean为P = 0.002)。
在我们的研究系列中,我们观察到COVID-19患者诊断时及恢复后肾上腺的F-FDG摄取持续较低,提示慢性功能减退。相比之下,疾病发作时甲状腺摄取与正常受试者相当,但恢复后,一部分患者显示代谢增加,因此可能提示炎性甲状腺炎的发生。我们的结果应提醒临床医生在感染时调查垂体 - 肾上腺轴和甲状腺功能,并在恢复后进行监测。